Open in App
  • U.S.
  • Election
  • Newsletter
  • The Associated Press

    Drugs to treat diabetes, heart disease and blood cancers among those affected by price negotiations

    2 hours ago
    https://img.particlenews.com/image.php?url=2q5AqS_0uyug3I900
    President Joe Biden speaks at the White House Creator Economy Conference in the Indian Treaty Room at the Eisenhower Executive Office Building on the White House complex, Wednesday, Aug. 14, 2024, in Washington. (AP Photo/Mark Schiefelbein)

    The Biden administration says Medicare recipients will save about $1.5 billion on out-of-pocket costs for medications to treat diabetes, heart disease, types of arthritis and other ailments under new prices negotiated with drug companies that will take effect in 2026.

    The savings range from 79% for Januvia, used to manage diabetes, to 38% for Imbruvica, which is used to treat blood cancers. That is the medication’s cost before any discounts or rebates are applied, but not what the price people actually pay when filling their prescriptions.

    A look at the drugs and the negotiated prices.

    Januvia

    Manufacturer: Merck Sharp Dohme

    Conditions: Diabetes

    Negotiated price: $113 for a 30-day supply

    Reduction: 79%

    Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill:

    Manufacturer: Novo Norodisk

    Conditions: Diabetes

    Negotiated price: $119 for a 30- day supply

    Reduction: 76%

    Farxiga

    Manufacturer: AstraZeneca AB.

    Conditions: Diabetes, heart failure and chronic kidney disease

    Negotiated price: $178.50 for a 30-day supply

    Reduction: 68%

    Enbrel

    Manufacturer: Immunex Corp.

    Conditions: Rheumatoid arthritis, psoriasis and psoriatic arthritis

    Negotiated price: $2,355 for a 30-day supply

    Reduction: 67%

    Jardiance

    Manufacturer: Boehringer Ingelheim

    Conditions: Diabetes, heart failure and chronic kidney disease

    Negotiated price: $197 for a 30-day supply

    Reduction: 66%

    Stelara

    Manufacturer: Janssen Biotech Inc.

    Conditions: Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis

    Negotiated price: $4,695 for a 30-day supply

    Reduction: 66%

    Xarelto

    Manufacturer: Janssen Pharms

    Conditions: Prevention and treatment of blood clots. Reduction of risk for patients with coronary or peripheral artery disease

    Negotiated price: $197 for a 30-day supply

    Reduction: 62%

    Eliquis

    Manufacturer: Bristol Myers Squibb

    Conditions: Prevention and treatment of blood clots

    Negotiated price: $231 for a 30-day supply

    Reduction: 56%

    Entresto

    Manufacturer: Novartis Pharms Corp

    Conditions: Heart failure

    Negotiated price: $295 for a 30-day supply

    Reduction: 53%

    Imbruvica

    Manufacturer: Pharmacyclics LLC

    Conditions: Blood cancers

    Negotiated price: $9,319 for a 30-day supply

    Savings: 38%

    Expand All
    Comments / 0
    Add a Comment
    YOU MAY ALSO LIKE
    Most Popular newsMost Popular
    easyhealthoptions.com14 days ago
    labroots.com16 days ago

    Comments / 0